These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38081992)

  • 1. The effect of orlistat in the treatment of non-alcoholic fatty liver in adolescents with overweight and obese.
    Zahmatkesh A; Sohouli MH; Shojaie S; Rohani P
    Eur J Pediatr; 2024 Mar; 183(3):1173-1182. PubMed ID: 38081992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.
    Namkhah Z; Naeini F; Mahdi Rezayat S; Mehdi Yaseri ; Mansouri S; Javad Hosseinzadeh-Attar M
    Int J Clin Pract; 2021 Nov; 75(11):e14852. PubMed ID: 34516703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for non-alcoholic fatty liver disease among obese and overweight children: Prevalence and predictors.
    Thiagarajan S; Shrinuvasan S; Arun Babu T
    Indian J Gastroenterol; 2022 Feb; 41(1):63-68. PubMed ID: 35064452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome.
    Esmail VAW; Mohammed MO; Al-Nimer MSM
    Arab J Gastroenterol; 2021 Mar; 22(1):1-5. PubMed ID: 33664007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of whole blood copper, zinc, calcium, magnesium, and iron with non-alcoholic fatty liver disease in overweight and obese children.
    Huang Z; Luo M; Dai W; Yao Z; Ouyang S; Xu N; Zhou H; Li X; Zhong Y; Luo J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Mar; 49(3):426-434. PubMed ID: 38970517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of green cardamom on blood glucose indices, lipids, inflammatory factors, paraxonase-1, sirtuin-1, and irisin in patients with nonalcoholic fatty liver disease and obesity: study protocol for a randomized controlled trial.
    Daneshi-Maskooni M; Keshavarz SA; Mansouri S; Qorbani M; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    Trials; 2017 Jun; 18(1):260. PubMed ID: 28592311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.
    Filippatos TD; Kiortsis DN; Liberopoulos EN; Georgoula M; Mikhailidis DP; Elisaf MS
    Curr Med Res Opin; 2005 Dec; 21(12):1997-2006. PubMed ID: 16368051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial.
    Jazayeri-Tehrani SA; Rezayat SM; Mansouri S; Qorbani M; Alavian SM; Daneshi-Maskooni M; Hosseinzadeh-Attar MJ
    Nutr Metab (Lond); 2019; 16():8. PubMed ID: 30705687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.
    Daneshi-Maskooni M; Keshavarz SA; Qorbani M; Mansouri S; Alavian SM; Badri-Fariman M; Jazayeri-Tehrani SA; Sotoudeh G
    BMC Complement Altern Med; 2019 Mar; 19(1):59. PubMed ID: 30871514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triglyceride glucose index, pediatric NAFLD fibrosis index, and triglyceride-to-high-density lipoprotein cholesterol ratio are the most predictive markers of the metabolically unhealthy phenotype in overweight/obese adolescent boys.
    Furdela V; Pavlyshyn H; Shulhai AM; Kozak K; Furdela M
    Front Endocrinol (Lausanne); 2023; 14():1124019. PubMed ID: 37234798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of naringenin supplementation in overweight/obese patients with non-alcoholic fatty liver disease: study protocol for a randomized double-blind clinical trial.
    Naeini F; Namkhah Z; Tutunchi H; Rezayat SM; Mansouri S; Jazayeri-Tehrani SA; Yaseri M; Hosseinzadeh-Attar MJ
    Trials; 2021 Nov; 22(1):801. PubMed ID: 34774104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of metabolic syndrome, insulin resistance and non-alcoholic fatty liver disease in overweight/obese children.
    El-Koofy NM; Anwar GM; El-Raziky MS; El-Hennawy AM; El-Mougy FM; El-Karaksy HM; Hassanin FM; Helmy HM
    Saudi J Gastroenterol; 2012; 18(1):44-9. PubMed ID: 22249092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
    Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
    Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Electroacupuncture combined with lifestyle control on obese nonalcoholic fatty liver disease: a randomized controlled trial].
    Dong C; Zhang CR; Xue BY; Miu WF; Fang NY; Li K; Ou ZJ; Xu YQ
    Zhongguo Zhen Jiu; 2020 Feb; 40(2):129-34. PubMed ID: 32100496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lipid metabolism in non-alcoholic fatty liver disease in patients with different body weights in mid-mountain conditions].
    Toktogulova NA; Sultanalieva RB; Tuhvatshin RR; Kaliev TK
    Ter Arkh; 2023 Jan; 94(12):1361-1366. PubMed ID: 37167179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Propolis supplementation in obese patients with non-alcoholic fatty liver disease: effects on glucose homeostasis, lipid profile, liver function, anthropometric indices and meta-inflammation.
    Nikbaf-Shandiz M; Tutunchi H; Khoshbaten M; Nazari Bonab H; Ebrahimi-Mameghani M
    Food Funct; 2022 Nov; 13(22):11568-11578. PubMed ID: 36263703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating future risk of NAFLD in adolescents: a prediction and decision curve analysis.
    Abeysekera KWM; Orr JG; Gordon FH; Howe LD; Hamilton-Shield J; Heron J; Hickman M
    BMC Gastroenterol; 2022 Jun; 22(1):323. PubMed ID: 35773644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D and nonalcoholic fatty liver disease in children: a randomized controlled clinical trial.
    El Amrousy D; Abdelhai D; Shawky D
    Eur J Pediatr; 2022 Feb; 181(2):579-586. PubMed ID: 34459959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Characteristics and Metabolic Profiles of Non-Alcoholic Fatty Liver Disease (NAFLD) in Lean Patients and Their Comparison with Obese and Overweight NAFLD.
    Chakrabarty M; Jha AN; Sharma DJ
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.